KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Intangibles (2021 - 2025)

Pacific Biosciences Of California (PACB) has 3 years of Intangibles data on record, last reported at $457.0 million in Q4 2023.

  • For Q4 2023, Intangibles rose 11.39% year-over-year to $457.0 million; the TTM value through Dec 2023 reached $457.0 million, up 11.39%, while the annual FY2023 figure was $457.0 million, 11.39% up from the prior year.
  • Intangibles reached $457.0 million in Q4 2023 per PACB's latest filing, down from $461.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $461.8 million in Q3 2023 and bottomed at $400.0 million in Q3 2021.
  • Average Intangibles over 3 years is $425.0 million, with a median of $410.6 million recorded in 2021.
  • Peak YoY movement for Intangibles: dropped 0.18% in 2022, then rose 11.39% in 2023.
  • A 3-year view of Intangibles shows it stood at $411.0 million in 2021, then decreased by 0.18% to $410.2 million in 2022, then rose by 11.39% to $457.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Intangibles were $457.0 million in Q4 2023, $461.8 million in Q3 2023, and $409.8 million in Q2 2023.